OTCMKTS:ATMS Artemis Therapeutics (ATMS) Stock Forecast, Price & News $1.89 +1.38 (+270.59%) (As of 05/19/2023 08:48 PM ET) Add Compare Share Share Today's Range$0.30▼$1.8950-Day Range$0.17▼$1.8952-Week Range$0.11▼$5.00Volume3,000 shsAverage Volume3,007 shsMarket Capitalization$211.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort InterestProfileChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest About Artemis Therapeutics (OTCMKTS:ATMS) StockArtemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.Read More Receive ATMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATMS Stock News HeadlinesMay 8, 2023 | msn.comMarker Therapeutics gets new chief medical officerApril 27, 2023 | finance.yahoo.comARTEMIS, a soccer-playing humanoid robot, is ready for the pitchMay 22, 2023 | UNKNOWN (Ad)This MMJ Stock Needs To Be At The Top Of Your Radar!With the MMJ Boom this one stock is separating itself from all the others for good reasonApril 23, 2023 | usatoday.comSpaceX Starship, larger and more powerful than Artemis SLS, explodes on first launch attemptMarch 18, 2023 | theguardian.comNasa reveals new spacesuit for Artemis moon landingJanuary 7, 2023 | finance.yahoo.comArtemis Therapeutics Inc. (ATMS)November 16, 2022 | cbsnews.comNASA managers order review of hurricane-damaged insulation before moon rocket launchNovember 10, 2022 | msn.comNASA’s Artemis I suffers ‘very minor’ damage from NicoleMay 22, 2023 | UNKNOWN (Ad)This MMJ Stock Needs To Be At The Top Of Your Radar!With the MMJ Boom this one stock is separating itself from all the others for good reasonOctober 10, 2022 | reuters.comArtemis Therapeutics IncSeptember 27, 2022 | yahoo.comArtemis I leaves launch pad ahead of Hurricane IanAugust 18, 2022 | news.yahoo.comNasa’s Artemis 1 moon mission explainedAugust 6, 2022 | yahoo.comNASA's Artemis I moon mission includes educational, cultural, and commemorative mementosJune 2, 2022 | finance.yahoo.comNASA Selects New Instruments for Priority Artemis Science on MoonMay 6, 2022 | msn.comWashington plays key role In NASA's Artemis missionsMarch 25, 2022 | yahoo.comCannes Chooses Former WarnerMedia Exec Iris Knobloch To Succeed Pierre Lescure As PresidentJuly 8, 2021 | in.finance.yahoo.comEureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple MyelomaApril 30, 2021 | in.finance.yahoo.comLendingPoint Recognized by Atlanta Business Chronicle’s Pacesetter Award for Fourth Consecutive YearApril 30, 2021 | ca.finance.yahoo.comCaution: Most Stocks Fail! Do This to Build a Winning Stock PortfolioApril 29, 2021 | au.finance.yahoo.comEssex Communities Announces New Leadership Structure to Accommodate Rapid GrowthApril 29, 2021 | au.finance.yahoo.com‘The Falcon and Winter Soldier’ fails to pay off on its initial promiseMarch 25, 2021 | yahoo.comAnother piebald deer stops by a trail camera for a photoMarch 25, 2021 | yahoo.comMum selling her possessions to fund £35K surgery before rare condition leaves her paralysedNovember 18, 2020 | seekingalpha.comLineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% UpsideJanuary 21, 2019 | finance.yahoo.comArtemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral InfectionsJanuary 21, 2019 | finance.yahoo.comNew Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV ReplicationJanuary 21, 2019 | finance.yahoo.comData Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV ReplicationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATMS Company Calendar Today5/21/2023Next Earnings (Estimated)5/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Miscellaneous chemical products Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ATMS CUSIPN/A CIK1062128 Webwww.artemis-therapeutics.com Phone(646) 233-1454Fax800-253-5177Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,360,000.00 Net MarginsN/A Pretax Margin-435.69% Return on EquityN/A Return on Assets-524.68% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.10 Sales & Book Value Annual Sales$310,000.00 Price / Sales683.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-189.00Miscellaneous Outstanding Shares112,030,000Free Float103,687,000Market Cap$211.74 million OptionableNot Optionable Beta-1.92 Key ExecutivesShimon CitronChief Executive Officer & DirectorHaim TabakChief Operating OfficerDavid DanaChief Financial OfficerDana WolfChief Medical OfficerKey CompetitorsPURE BioscienceOTCMKTS:PUREPurple BiotechNASDAQ:PPBTCASI PharmaceuticalsNASDAQ:CASIPositronOTCMKTS:POSCYumanity TherapeuticsNASDAQ:YMTXView All Competitors ATMS Stock - Frequently Asked Questions How have ATMS shares performed in 2023? Artemis Therapeutics' stock was trading at $1.16 on January 1st, 2023. Since then, ATMS shares have increased by 62.9% and is now trading at $1.89. View the best growth stocks for 2023 here. Are investors shorting Artemis Therapeutics? Artemis Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 100 shares, a drop of 83.3% from the March 31st total of 600 shares. Based on an average trading volume of 4,000 shares, the short-interest ratio is currently 0.0 days. View Artemis Therapeutics' Short Interest. When is Artemis Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 22nd 2023. View our ATMS earnings forecast. What is Artemis Therapeutics' stock symbol? Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS." How do I buy shares of Artemis Therapeutics? Shares of ATMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Artemis Therapeutics' stock price today? One share of ATMS stock can currently be purchased for approximately $1.89. How much money does Artemis Therapeutics make? Artemis Therapeutics (OTCMKTS:ATMS) has a market capitalization of $211.74 million and generates $310,000.00 in revenue each year. How can I contact Artemis Therapeutics? Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The official website for the company is www.artemis-therapeutics.com. The company can be reached via phone at (646) 233-1454, via email at ir@artemis-therapeutics.com, or via fax at 800-253-5177. This page (OTCMKTS:ATMS) was last updated on 5/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artemis Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.